Some preclinical studies and case reports have shown that therapeutic blockade of PDGFRβ with agents like imatinib in combination with ALK inhibitors can lead to significant reduction in size of tumor mass and alleviate relapse of ALCLs after exposure to single agent ALK inhibitors163. This evidence concerns the gene ALK and neoplasm.